Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066742 · ClinicalTrials.gov registry record · Phase 2
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
A Phase 2 study of Limited Stage Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00066742 is a Phase 2 study of Limited Stage Small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 301-participant average among 4 other Limited Stage Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00066742, a Phase 2 study of Limited Stage Small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving tirapazamine together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tirapazamine may make the tumor cells more sensitive to chemotherapy and radiation therapy. Combining chemotherapy and radiation therapy with tirapazamine may kill more tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- DRUG etoposide
- RADIATION radiation therapy
- DRUG tirapazamine
Study Locations (1)
Texas
- Southwest Oncology Group (SWOG) Research Base - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066742
The ClinicalTrials.gov registry entry for NCT00066742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 4 other Limited Stage Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Limited Stage Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00066742 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00066742 about?
NCT00066742 is a clinical study titled "Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer". This phase II trial is studying how well giving tirapazamine together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop tumor cells from di...
What is the current status of trial NCT00066742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2003-09. Estimated completion is 2009-08.
What conditions does trial NCT00066742 study?
This clinical trial studies the following conditions: Limited Stage Small Cell Lung Cancer.
What interventions are being tested in trial NCT00066742?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), tirapazamine (DRUG).
Who is sponsoring clinical trial NCT00066742?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00066742 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Limited Stage Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
RECRUITING · Phase 2
-
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
COMPLETED · Phase 2
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.